Sridevi Rajeeve, MD

@sridevirajeeve

⚕️Asst. Attending Myeloma & Cell Therapy @MSKCancerCenter via @MountSinaiNYC @TischCancer 🇮🇳➡️🇺🇸 Interests: #MMsm #CART #cellulartherapy

New York, NY

Joined August 2009

2KFollowing

2KFollowers

Pinned

Sridevi Rajeeve, MD@sridevirajeeve · Jun 4, 2022

Amazing evening receiving the @ASCO @ConquerCancerFd Young Investigator Award (YIA) 2022. Thankful to my stellar mentor Dr. Samir Parekh at @IcahnMountSinai & @TischCancer @SinaiHemeOnc for the support! #ASCO22 📸3: friends, old and new @drsomedeb 📸4: proud hubby @suchithnair

sridevirajeeve's tweet image. Amazing evening receiving the @ASCO @ConquerCancerFd Young Investigator Award (YIA) 2022. Thankful to my stellar mentor Dr. Samir Parekh at @IcahnMountSinai &amp; @TischCancer @SinaiHemeOnc for the support! #ASCO22
📸3: friends, old and new @drsomedeb
📸4: proud hubby @suchithnair

Sridevi Rajeeve, MD Retweeted

Mike Thompson, MD, PhD, FASCO@mtmdphd · Jun 18

Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group [Jun 18, 2025] Lu et al. @lbaughn @BloodCancerJnl nature.com/articles/s4140… #mmsm #hemepath…

5.0K

Sridevi Rajeeve, MD Retweeted

Francesco Maura@FrancescoMaura4 · Jun 11

Happy to share our new work out today on @BloodPortfolio #Blood where we report CD38 loss as recurrent mechanisms of resistance to anti-CD38 antibody in multiple myeloma. Great collaboration between @MSKCancerCenter @MSK_DeptOfMed @UCalgary @HDMyeloma @MayoClinic #mmsm #wgs

5.0K

Sridevi Rajeeve, MD Retweeted

Vincent Rajkumar@VincentRK · May 7

We call for a paradigm shift in development of immunotherapy drugs, especially bispecifics. @LeukemiaJnl These drugs have therapeutic effects that last a long time. We need to reduce frequency and switch to limited duration treatment to avoid toxicity. nature.com/articles/s4137…

10.0K

Sridevi Rajeeve, MD@sridevirajeeve · May 9

Early results in patients who had failed prior CAR T: → 81% overall response → 52% complete remission at 3 months → 3-day manufacturing turnaround This research from @carlhjune and team represents the first IL-18–secreting CAR T tested in blood cancer — and it may reshape…

PParker Institute for Cancer Immunotherapy@parkerici · May 8

For patients with lymphoma that relapses after CAR T, clinical options become vanishingly few. Now, a new study in @NEJM led by @carlhjune, Director of the PICI Center @PennMedicine, offers a new approach: huCART19-IL18 –– an IL-18–secreting, “armored” CAR T-cell.…

4.0K

Sridevi Rajeeve, MD Retweeted

DAVA Oncology@DAVAOnc · Apr 3

Dr. @RahulBanerjeeMD from @fredhutch talks on #Cevostamab: A “third-party candidate” in myeloma? ✅ FcRH5 target, maintained post-BCMA exposure ✅ Manageable safety, fewer infections vs. BCMA bsAbs ✅ No GPRC5D toxicities ⏳ Needs better efficacy/durability! #DAVAWhistler

2.0K

Sridevi Rajeeve, MD@sridevirajeeve · Mar 21

Looking forward to the inaugural #iwGPRC5D International Workshop on GPRC5D-Targeted Myeloma Therapies on March 22 in NYC! iwgprc5d.org/agenda/ Excited to learn & share our collective knowledge on the next frontier beyond BCMA. @szusmani @ShamMailankody @NoopurRajeMD ...

sridevirajeeve's tweet image. Looking forward to the inaugural #iwGPRC5D International Workshop on GPRC5D-Targeted Myeloma Therapies on March 22 in NYC! iwgprc5d.org/agenda/
Excited to learn &amp; share our collective knowledge on the next frontier beyond BCMA.
@szusmani @ShamMailankody @NoopurRajeMD ...

2.0K

Sridevi Rajeeve, MD Retweeted

Rahul Banerjee, MD, FACP@RahulBanerjeeMD · Jan 31

So excited!! Welcome @UrviShahMD to @fredhutch Grand Rounds. I’m glad you joined by Zoom since shockingly it is raining today in Seattle for the first time in 2 weeks :) Cc @MSKCancerCenter @szusmani @sridevirajeeve @GunjanLShah @MScordoMD #MMsm

5.0K

Sridevi Rajeeve, MD Retweeted

Memorial Sloan Kettering Cancer Center@MSKCancerCenter · Jan 17

MSK is the first hospital in New York City to offer gene therapy for #sicklecelldisease and beta thalassemia through its pediatric program, MSK Kids. “Following our leadership in gene therapy clinical trials, this authorization expands our treatment options for these…

5.0K

Sridevi Rajeeve, MD Retweeted

Joshua Richter, MD, FACP@JoshuaRichterMD · Jan 4

Congrats to ⁦@RahulBanerjeeMD⁩ ⁦@VincentRK⁩ ⁦@szusmani⁩ ⁦@Myeloma_Doc⁩ ⁦@myelomaMD⁩ et al for this extremely clinically impactful paper! #mmsm ashpublications.org/blood/article/…

112

9.0K

Sridevi Rajeeve, MD@sridevirajeeve · Dec 10

#ASH24 📊: Daratumumab vs lenalidomide maintenance in NDMM TE+TI, 1:1 randomized IIT @MSKCancerCenter. n=87 (39 dara, 38 len). Similar (numerically ⬆️) 12mPFS, 24mPFS, >=CR & MRD- rates with fewer drug discontinuation on dara arm. 66% prior dara exposure. @UrviShahMD @szusmani

sridevirajeeve's tweet image. #ASH24 📊: Daratumumab vs lenalidomide maintenance in NDMM TE+TI, 1:1 randomized IIT @MSKCancerCenter.
n=87 (39 dara, 38 len). Similar (numerically ⬆️) 12mPFS, 24mPFS, &gt;=CR &amp; MRD- rates with fewer drug discontinuation on dara arm. 66% prior dara exposure. @UrviShahMD @szusmani

11.0K

Sridevi Rajeeve, MD Retweeted

Vincent Rajkumar@VincentRK · Dec 9

Just out: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma #ASH24 @thanosdimop @NEJM Daratumumab significantly prolongs time to active myeloma and overall survival. Proud to be a lead investigator of this trial nejm.org/doi/full/10.10… Slides in thread

127

347

111

80.0K

Sridevi Rajeeve, MD Retweeted

Rahul Banerjee, MD, FACP@RahulBanerjeeMD · Dec 9

Out in @NEJM as @thanosdimop is speaking!! 🚨 Most important #ASH24 abstract in #MMsm: AQUILA study demonstrating OS benefit with dara x3 years in high-risk SMM. Monthly dara now can prevent Dara quad & ASCT later? Will be worth it in some patients! nejm.org/doi/full/10.10…

7.0K

Sridevi Rajeeve, MD Retweeted

Rahul Banerjee, MD, FACP@RahulBanerjeeMD · Dec 7

1/ Easily the most provocative #MMsm oral abstract of #ASH24 🤔 Does transplantation interfere with subsequent CAR-T efficacy? Gustine et al @andrew02114 @NoopurRajeMD Part 1 - setting the stage Why high-dose melphalan might interfere with T-cell fitness…

12.0K

Sridevi Rajeeve, MD Retweeted

Ben Derman@bdermanmd · Oct 9

What happens when patients with myeloma and sustained MRD negativity choose to discontinue maintenance? We sought to answer this question in our study MRD2STOP, out now in @BloodCancerJnl nature.com/articles/s4140…

151

26.0K

Sridevi Rajeeve, MD Retweeted

MSK Department of Medicine@MSK_DeptOfMed · Dec 7

Join myeloma specialist Dr. Kylee Maclachlan for the presentation "Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease." 2:15 pm PST at #ASH24. @MSKCancerCenter @szusmani buff.ly/4f6J3gP

4.0K

Sridevi Rajeeve, MD Retweeted

Hamza Hashmi@hhashmi87 · Dec 6

Hot off the press in @BloodCancerJnl Salvage therapy for post CAR T relapse: Are BiTES the right choice? n=139 (mostly idecel), relapse <5m,>50% EMD RR:Talq (80%), Tec (65%), IMiD/PI/CD38 (30%),Other (25%) ⬆️⬆️DoR, PFS, OS w BsAb vs Others regardless of EMD, timing of relapse.

3.0K